American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Chemoradiation or Cetuximab/Radiation Versus Induction Chemotherapy Followed by Chemoradiation in Locally Advanced SCCHN

ASCO 2014 – Colorectal and Head & Neck Cancer

Platinum-based chemoradiation therapy (CRT) is the current standard treatment for locally advanced SCCHN, and induction docetaxel/cisplatin/5-fluorouracil (TPF) is superior to cisplatin/5-fluorouracil alone, but it has not been tested when added to concomitant therapy. Read More ›

The E1308 Trial: Reduced-Dose IMRT in HPV-Associated OPSCC After Induction Chemotherapy

ASCO 2014 – Colorectal and Head & Neck Cancer

In the E2399 trial, HPV+ patients with oropharyngeal squamous cell carcinoma (OPSCC) attained 2-year overall survival (OS) of 95% and progression-free survival (PFS) of 86% when treated with induction chemotherapy (IC) and 70 Gy chemoradiation. Read More ›

RTOG 0522: The KRAS Variant and Response to Cetuximab

ASCO 2014 – Colorectal and Head & Neck Cancer

In many cancers, KRAS mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents. RTOG 0522 was a phase 3 trial of cisplatin/radiation ± cetuximab for patients with locally advanced SCCHN, evaluating whether KRAS mutation status would predict the response to cetuximab in these patients (Weidhaas JB, et al. ASCO 2014. Abstract 6000). Read More ›

Adjuvant Lapatinib Plus Chemoradiation in High-Risk Patients with SCCHN

ASCO 2014 – Colorectal and Head & Neck Cancer

Final Results of the CAIRO3 Study

ASCO 2014 – Colorectal and Head & Neck Cancer